Rare diseases affect small groups of patients and are often life-threatening or causing chronic disability. In total there are about 7,000 known rare diseases but only about 400 approved treatments.

Sobi’s product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies.

Swedish Orphan Biovitrum UK believes in transparency. Payments made to healthcare professionals and their staff, funding to patient groups, support made to organisations and sponsorship for delegates to attend congresses are declared as per the ABPI code of practice.